GRAIL Reports Full Results From NHS-Galleri Trial Demonstrating Substantial Reduction in Stage IV Cancer Diagnoses at 2026 ASCO Annual Meeting

No Reduction Observed in Combined Primary Endpoint of Stage III/IV Cancers in Aggregate; However, Decreases Observed Beyond the Prevalent Screening Round

Annual Galleri® Blood Test Reduced Stage IV Diagnoses of 12 Prespecified Cancers by 22% and 26% in the Second and Third Screening Rounds, Respectively

Galleri Increased Cancer Detection Rate by Four-Fold When Added to Standard of Care Screening and Reduced Cancer Diagnosis Through Emergency Presentation by 25%

Annual Testing With Galleri Increased Stage I-II Cancer Diagnoses by 16% When Added to Standard of Care

GRAIL to Host Analyst Call From 2026 ASCO Annual Meeting

MENLO PARK, Calif., May 30, 2026 — GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced detailed clinical utility, performance and safety results from its landmark NHS-Galleri trial in an oral presentation at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting1.

GRAIL reports full results from NHS-Galleri Trial demonstrating substantial reduction in Stage IV cancer diagnoses at 2026 ASCO Annual Meeting

if video/audio/not yotube

Speed

Speed

This is the section for extra SEO content!

Ann, NHS-Galleri Trial participant

if video/audio/not yotube

Speed

Speed

This is the section for extra SEO content!

NHS-Galleri Trial Film

if video/audio/not yotube

Speed

Speed

This is the section for extra SEO content!

NHS-Galleri Trial: Percent difference in Stage IV cancers

if video/audio/not yotube

NHS-Galleri Trial: Stage I&II Cancers

if video/audio/not yotube

NHS-Galleri Trial: Screen detected cancers

if video/audio/not yotube

View PDF

NHS-Galleri Trial Fact Sheet

if video/audio/not yotube